0 results available. Select is focused ,type to refine list, press Down to open the menu,
GSK plc, together with its subsidiaries, engages in the research, development, and manufacture of vaccines, and specialty and general medicines to prevent and treat disease in the United Kingdom, the ...
We've identified the following companies as similar to GSK plc DRC because they operate in a related industry or sector. We also considered size, growth, and various financial metrics to narrow down the list to the ones listed below.
| Name | Ticker | FCF Levered Cumulative Growth (3y) |
|---|---|---|
| Kyorin Holdings Inc | TSE:4569 | -476.9% |
| GSK plc DRC | NYSE:GSK | -26.4% |
| Viatris Inc. | LSE:0A5V | -22.8% |
| Sanofi L | LSE:0O59 | -18.8% |
| Healthcare | SECTOR:HLTH.GB | -12.5% |
| Ipsen L | LSE:0MH6 | -7.8% |
| Roche Holding AG Participation | LSE:0QOK | -4.2% |
| Dr Reddy’s Laboratories Ltd | BSE:500124 | 11.8% |
| Novartis AG | LSE:0QLR | 16.1% |
| Merck & Co Inc | LSE:0QAH | 87.3% |
| AstraZeneca PLC | LSE:AZN | 104.0% |
| Genomma Lab Internacional SAB De CV | BMV:LABB | 229.6% |
To view the full list of supported financial metrics please see Complete Metrics Listing.
Cumulative levered free cash flow growth over the last three years
The chart above depicts the distribution of fcf levered cumulative growth (3y) for companies operating in the Healthcare sector in the Developed economic region. Over 1,950 companies were considered in this analysis, and 1,881 had meaningful values. The average fcf levered cumulative growth (3y) of companies in the sector is -21.9% with a standard deviation of 196.6%.
GSK plc DRC's FCF Levered Cumulative Growth (3y) of -26.4% ranks in the 40.0% percentile for the sector. The following table provides additional summary stats:
| Economic Risk Region | Developed |
| Total Constituents | 1,958 |
| Included Constituents | 1,881 |
| Min | -1,245.1% |
| Max | 694.2% |
| Median | 6.1% |
| Mean | -21.9% |
| Standard Deviation | 196.6% |
You can find companies with similar fcf levered cumulative growth (3y) using this stock screener.